Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: An 11C altropane positron emission tomography study

Alzheimer's Research and Therapy

Volumn 6, Issue 8, 2014, Pages

  Marquie, Marta ^a,b   Locascio, Joseph J ^a   Rentz, Dorene M ^a   Becker, J Alex ^a   Hedden, Trey ^a   Johnson, Keith A ^a   Growdon, John H ^a   Gomperts, Stephen N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTROPANE; CARBON 11; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA;

AGED; ANTERIOR CINGULATE; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; CORTICAL THICKNESS (BRAIN); DEPTH PERCEPTION; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; EPISODIC MEMORY; EXECUTIVE FUNCTION; EXTRASTRIATE BODY AREA; FEMALE; HUMAN; LANGUAGE; MALE; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SCANNER; ORBITAL CORTEX; PARKINSON DISEASE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PUTAMEN; SEMANTIC MEMORY;

EID: 84907058368     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0052-7     Document Type: Article

References (64)

1. Schulz-Schaeffer WJ: The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010, 120:131-143.
2. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D., Schmidt ML, Lee VM, Clark CM, Glosser G, Stern M.B., Gollomp SM, Arnold SE: Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54:1916-1921.
3. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton J.L., Collins C., Lashley T, Kallis C, Williams D.R., de Silva R, Lees AJ, Revesz T: Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011, 134:1493-1505.
4. Zgaljardic DJ, Foldi NS, Borod JC: Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J Neural Transm 2004, 111:1287-1301.
5. Brooks DJ: Dopaminergic action beyond its effects on motor function: imaging studies. J Neurol 2006, 253:IV8-IV15.
6. Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986, 9:357-381.
7. Schultz W, Dayan P, Montague PR: A neural substrate of prediction and reward. Science 1997, 275:1593-1599.
8. Sesack SR, Hawrylak VA, Matus C, Guido M.A., Levey AI: Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 1998, 18:2697-2708.
9. Lewis DA, Melchitzky DS, Sesack S.R., Whitehead RE, Auh S, Sampson A: Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol 2001, 432:119-136.
10. Brooks DJ, Piccini P: Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry 2006, 59:908-918.
11. Amara SG, Kuhar MJ: Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993, 16:73-93.
12. Tian L, Karimi M, Loftin S.K., Brown CA, Xia H, Xu J, Mach R.H., Perlmutter JS: No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 2012, 7:e31439.
13. Pirker W: Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003, 18:S43-S51.
14. Wang J, Zuo CT, Jiang Y.P., Guan YH, Chen ZP, Xiang JD, Yang L.Q., Ding ZT, Wu JJ, Su HL: 18 F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 2007, 254:185-190.
15. Berger HJ, Cools AR, Horstink M.W., Oyen WJ, Verhoeven EW, van der Werf SP: Striatal dopamine and learning strategy-an (123)I-FP-CIT SPECT study. Neuropsychologia 2004, 42:1071-1078.
16. Muller U, Wachter T, Barthel H., Reuter M, von Cramon DY: Striatal [123I] beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 2000, 107:303-319.
17. Fischman AJ, Bonab AA, Babich J.W., Livni E., Alpert NM, Meltzer PC, Madras BK: [(11)C, (127)I] altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 2001, 39:332-342.
18. Elmaleh DR, Fischman AJ, Shoup T.M., Byon C., Hanson RN, Liang AY, Meltzer PC, Madras BK: Preparation and biological evaluation of iodine-125-IACFT: a selective SPECT agent for imaging dopamine transporter sites. J Nucl Med 1996, 37:1197-1202.
19. Seibyl JP, Marek K, Sheff K., Zoghbi S, Baldwin RM, Charney D.S., van Dyck CH, Innis RB: Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998, 39:1500-1508.
20. Abi-Dargham A., Gandelman MS, DeErausquin G.A., Zea-Ponce Y, Zoghbi SS, Baldwin R.M., Laruelle M., Charney DS, Hoffer PB, Neumeyer JL, Innis RB: SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996, 37:1129-1133.
21. Hu XS, Okamura N, Arai H., Higuchi M, Matsui T, Tashiro M., Shinkawa M, Itoh M, Ido T., Sasaki H: 18 F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000, 55:1575-1577.
22. Rakshi JS, Uema T, Ito K., Bailey DL, Morrish PK, Ashburner J, Dagher A., Jenkins IH, Friston KJ, Brooks DJ: Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 1999, 122:1637-1650.
23. Klein JC, Eggers C, Kalbe E., Weisenbach S, Hohmann C, Vollmar S., Baudrexel S, Diederich NJ, Heiss W.D., Hilker R: Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010, 74:885-892.
24. Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993, 50:140-148.
25. McKeith IG, Dickson DW, Lowe J, Emre M., O'Brien JT, Feldman H, Cummings J., Duda JE, Lippa C, Perry EK, Aarsland D, Arai H., Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
26. Hughes CP, Berg L, Danziger W.L., Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982, 140:566-572.
27. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
28. Lange KW, Paul GM, Robbins T.W., Marsden CD: L-dopa and frontal cognitive function in Parkinson's disease. Adv Neurol 1993, 60:475-478.
29. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
30. Lang A, Fahn S: Assessment of Parkinson's disease. In Quantification of Neurologic Deficit. Edited by Munstat. Boston, MA: Butterworths; 1989:285-309.
31. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
32. Weschler D: The Wechsler Memory Scale. San Antonio, TX: The Psychological Corporation; 1997.
33. Grober E, Lipton RB, Hall C, Crystal H: Memory impairment on free and cued selective reminding predicts dementia. Neurology 2000, 54:827-832.
34. Benton AL, Varney NR, Hamsher K.D., Varney NR, Spreen O: Contributions to Neuropsychological Assessment. Oxford: Oxford University Press; 1983.
35. Monsch AU, Bondi MW, Butters N, Salmon D.P., Katzman R., Thal LJ: Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol 1992, 49:1253-1258.
36. Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test: Assessment of Aphasia and Related Disorders. 2nd edition. Philadelphia, PA: Lea & Febiger; 1983.
37. Weschler D: WAIS-III, Weschler Adult Intelligence Scale - Third Edition, Administration and Scoring Manual. New York: The Psychological Corporation; 1997.
38. Reitan R: Manual for Administration of Neuropsychological Test Batteries for Adults and Children. Reitan Neuropsychology Laboratories: Tucson, AZ; 1979.
39. Tomlinson CL, Stowe R, Patel S., Rick C, Gray R, Clarke CE: Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2653.
40. Gomperts SN, Locascio JJ, Marquie M, Santarlasci A.L., Rentz DM, Maye J, Johnson KA, Growdon JH: Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012, 27:965-973.
41. Dale AM, Fischl B, Sereno MI: Cortical surface-based analysis, I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
42. Freesurfer. [http://surfer.nmr.mgh.harvard.edu].
43. Fischl B, Sereno MI, Tootell R.B., Dale AM: High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp 1999, 8:272-284.
44. Desikan RS, Segonne F, Fischl B., Quinn BT, Dickerson BC, Blacker D, Buckner R.L., Dale AM, Maguire RP, Hyman BT, Albert M.S., Killiany RJ: An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006, 31:968-980.
45. Thie JA: Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004, 45:1431-1434.
46. Becker JA, Hedden T, Carmasin J., Maye J, Rentz DM, Putcha D, Fischl B., Greve DN, Marshall GA, Salloway S, Marks D., Buckner RL, Sperling RA, Johnson KA: Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011, 69:1032-1042.
47. Walker Z, Costa DC, Walker R.W., Lee L., Livingston G, Jaros E, Perry R., McKeith I, Katona CL: Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004, 62:1568-1572.
48. Seibyl JP, Marek KL, Quinlan D, Sheff K., Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith E.O., Charney DS, Hoffer PB, Innis RB: Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995, 38:589-598.
49. Taylor JP, Colloby SJ, McKeith I.G., Burn DJ, Williams D, Patterson J, O'Brien JT: Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2007, 78:1069-1071.
50. Walker Z, Costa DC, Walker R.W., Shaw K., Gacinovic S, Stevens T, Livingston G., Ince P, McKeith IG, Katona CL: Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002, 73:134-140.
51. Colloby SJ, O'Brien JT, Fenwick JD, Firbank M.J., Burn DJ, McKeith IG, Williams ED: The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004, 23:956-966.
52. Song IU, Kim YD, Cho H.J., Chung SW, Chung YA: An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord 2013, 27:51-55.
53. Marie RM, Barre L, Dupuy B., Viader F, Defer G, Baron JC: Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 1999, 260:77-80.
54. Bruck A, Portin R, Lindell A., Laihinen A, Bergman J, Haaparanta M., Solin O, Rinne JO: Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001, 311:81-84
55. Jokinen P, Bruck A, Aalto S., Forsback S, Parkkola R, Rinne JO: Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009, 15:88-93.
56. Bezard E, Dovero S, Prunier C., Ravenscroft P, Chalon S, Guilloteau D., Crossman AR, Bioulac B, Brotchie JM, Gross CE: Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001, 21:6853-6861
57. Nandhagopal R, Kuramoto L, Schulzer M., Mak E, Cragg J, McKenzie J., McCormick S, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Stoessl AJ: Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011, 134:3290-3298
58. Sawaguchi T, Goldman-Rakic PS: The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 1994, 71:515-528
59. Cools R, D'Esposito M: Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 2011, 69:e113-e125.
60. Nemani VM, Lu W, Berge V., Nakamura K, Onoa B, Lee M.K., Chaudhry FA, Nicoll RA, Edwards RH: Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79
61. Dubois B, Ruberg M, Javoy-Agid F, Ploska A., Agid Y: A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res 1983, 288:213-218
62. Williams SM, Goldman-Rakic PS: Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 1998, 8:321-345
63. Kaenmaki M, Tammimaki A, Myohanen T., Pakarinen K, Amberg C, Karayiorgou M., Gogos JA, Mannisto PT: Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem 2010, 114:1745-1755.
64. Delli Pizzi S., Franciotti R, Tartaro A., Caulo M, Thomas A, Onofrj M., Bonanni L: Structural alteration of the dorsal visual network in DLB patients with visual hallucinations: a cortical thickness MRI study. PLoS One 2014, 9:e86624.